407 related articles for article (PubMed ID: 33284169)
1. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
Abdu FA; Liu L; Mohammed AQ; Xu B; Yin G; Xu S; Xu Y; Che W
J Cardiovasc Pharmacol; 2020 Dec; 76(6):678-683. PubMed ID: 33284169
[TBL] [Abstract][Full Text] [Related]
2. Impact of secondary prevention medical therapies on outcomes of patients suffering from Myocardial Infarction with NonObstructive Coronary Artery disease (MINOCA): A meta-analysis.
De Filippo O; Russo C; Manai R; Borzillo I; Savoca F; Gallone G; Bruno F; Ahmad M; De Ferrari GM; D'Ascenzo F
Int J Cardiol; 2022 Dec; 368():1-9. PubMed ID: 35987312
[TBL] [Abstract][Full Text] [Related]
3. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry.
Tea V; Bonaca M; Chamandi C; Iliou MC; Lhermusier T; Aissaoui N; Cayla G; Angoulvant D; Ferrières J; Schiele F; Simon T; Danchin N; Puymirat E;
Eur J Prev Cardiol; 2019 Mar; 26(4):411-419. PubMed ID: 30354737
[TBL] [Abstract][Full Text] [Related]
4. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
Circulation; 2017 Apr; 135(16):1481-1489. PubMed ID: 28179398
[TBL] [Abstract][Full Text] [Related]
5. Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
Nordenskjöld AM; Agewall S; Atar D; Baron T; Beltrame J; Bergström O; Erlinge D; Gale CP; López-Pais J; Jernberg T; Johansson P; Ravn-Fisher A; Reynolds HR; Somaratne JB; Tornvall P; Lindahl B
Am Heart J; 2021 Jan; 231():96-104. PubMed ID: 33203618
[TBL] [Abstract][Full Text] [Related]
6. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
7. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and Predictors of Mortality in Patients Suffering Myocardial Infarction With Non-Obstructive Coronary Arteries.
Choo EH; Chang K; Lee KY; Lee D; Kim JG; Ahn Y; Kim YJ; Chae SC; Cho MC; Kim CJ; Kim HS; Jeong MH;
J Am Heart Assoc; 2019 Jul; 8(14):e011990. PubMed ID: 31284804
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
10. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
[TBL] [Abstract][Full Text] [Related]
11. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
Figtree GA; Vernon ST; Hadziosmanovic N; Sundström J; Alfredsson J; Arnott C; Delatour V; Leósdóttir M; Hagström E
Lancet; 2021 Mar; 397(10279):1085-1094. PubMed ID: 33711294
[TBL] [Abstract][Full Text] [Related]
12. Use of secondary prevention medications in metropolitan and non-metropolitan areas: an analysis of 41 925 myocardial infarctions in Australia.
Livori AC; Ademi Z; Ilomäki J; Pol D; Morton JI; Bell JS
Eur J Prev Cardiol; 2024 Mar; 31(5):580-588. PubMed ID: 37987181
[TBL] [Abstract][Full Text] [Related]
13. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
Byun JK; Choi BG; Rha SW; Choi SY; Jeong MH;
Atherosclerosis; 2018 Oct; 277():130-135. PubMed ID: 30212681
[TBL] [Abstract][Full Text] [Related]
14. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme Inhibitor-based Versus Angiotensin Receptor Blocker-based Optimal Medical Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
J Cardiovasc Pharmacol; 2021 Jan; 77(1):61-68. PubMed ID: 33165139
[TBL] [Abstract][Full Text] [Related]
16. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
[TBL] [Abstract][Full Text] [Related]
17. Optimizing prevention and guideline-concordant care in Montenegro.
Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
[TBL] [Abstract][Full Text] [Related]
19. Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry - National Institute of Health.
Ahn JH; Hyun JY; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim MC; Park HS; Kim DI; Hur SH; Oh SK; Ahn Y
Cardiol J; 2021; 28(5):738-745. PubMed ID: 33001422
[TBL] [Abstract][Full Text] [Related]
20. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
